million people around the world quit smoking and, as a result, have
significantly reduced their exposure to the risks of cancer and other
-- More than one billion patches, lozenges and gums were sold in 2007 to
help smokers quit.(5)
-- Quitters using therapeutic nicotine can double their chances of success
versus quitting without help.
-- More than 110 studies involving approximately 40,000 smokers have
demonstrated the safety of therapeutic nicotine, even in populations
with specific health conditions, such as diabetes, high blood pressure,
lung disease, and existing heart disease.(6)
-- International and national guidelines from the United States, United
Kingdom and the World Health Organization (WHO) recommend therapeutic
nicotine as a first-line treatment for smoking addiction.(7)
-- Committed Quitters is the only free, tailored Web-based behavioral
support program that has been proven to increase a smoker's chances of
quitting. This program is available as Click2Quit in the UK.
-- More than 13 billion packs of cigarettes have gone un-sold as a result
of smokers quitting with therapeutic nicotine.(8)
GlaxoSmithKline's line of therapeutic nicotine products such as Nicorette gum (United States only), NicoDerm CQ patch and Commit lozenge, and NiQuitin and Nicabate brands outside of the United States, are easy to access in thousands of retail outlets and pharmacies worldwide. These products are designed specifically to break the daily addiction cycle by offering a gradual, controlled delivery of nicotine to the body, helping to relieve cravings and withdrawal symptoms.
About GlaxoSmithKline Consumer Healthcare
GlaxoSmithKline Consumer Healthcare is one of the world's largest
|SOURCE GlaxoSmithKline Consumer Healthcare|
Copyright©2008 PR Newswire.
All rights reserved